Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bébéar, C. M.
Right arrow Articles by Bébéar, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bébéar, C. M.
Right arrow Articles by Bébéar, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 711-714
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas

Cécile M. Bébéara,*, Hélène Renaudina, Thierry Schaeverbekea, Françoise Leblancb and Christiane Bébéara

a Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux cedex; b GlaxoWellcome, 100 Route de Versailles, 78163 Marly le Roi, France

The in-vitro activity of grepafloxacin, a new oral fluoroquinolone antibiotic, was compared with those of three other fluoroquinolones and two unrelated antimicrobials, doxycycline and erythromycin, against various Mycoplasma spp. For 65 mycoplasma and 42 ureaplasma strains, grepafloxacin (MIC range 0.03- 2 mg/L) was some two to 16 times more active than ofloxacin and ciprofloxacin, showing similar activity to that of sparfloxacin. MBCs of grepafloxacin increased two- to 16-fold when compared with MICs and were comparable to those of sparfloxacin, and lower than those of ofloxacin and ciprofloxacin.

* Tel: +33-5-57-16-25; Fax: +33-5-56-79-60-42; E-mail: cecile.bebear{at}u-bordeaux2.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. B. Waites, D. M. Crabb, X. Bing, and L. B. Duffy
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 161 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Bebear, H. Renaudin, A. Charron, D. Gruson, M. Lefrancois, and C. Bebear
In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas Including Mycoplasma hominis and Ureaplasma urealyticum Fluoroquinolone-Resistant Isolates That Have Been Genetically Characterized
Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2557 - 2560.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Bebear, H. Renaudin, A. Bryskier, and C. Bebear
Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1980 - 1982.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
P. C. T. Hannan and G. Woodnutt
In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas
J. Antimicrob. Chemother., March 1, 2000; 45(3): 367 - 369.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.